New drug trial aims to ease droopy eyelids and double vision

NCT ID NCT07463521

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an investigational drug called rozanolixizumab against a placebo in 120 adults with ocular myasthenia gravis, a condition causing eye muscle weakness like droopy eyelids or double vision. Participants receive the drug or placebo by injection, and researchers measure changes in eye symptoms after about 6 weeks. The goal is to see if the drug safely reduces symptom severity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULAR MYASTHENIA GRAVIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mg0038 10103
RECRUITING

Columbus, Ohio, 43210, United States
Mg0038 10106
RECRUITING

Amherst, New York, 14226, United States